Following on from information provided to NICE by the company in December 2017, the appraisal of Selumetinib for treating differentiated thyroid cancer [ID1079] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1079 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 31 October 2022 | Following on from information provided to NICE by the company in December 2017, the appraisal of Selumetinib for treating differentiated thyroid cancer [ID1079] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 31 October 2022 | Discontinued. Following on from information provided to NICE by the company in December 2017, the appraisal of Selumetinib for treating differentiated thyroid cancer [ID1079] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 02 August 2017 | In progress. In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual